Investigational
Showing 1 - 25 of >10,000
Tuberculosis Trial in Worldwide (M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine, Placebo)
Not yet recruiting
- Tuberculosis
- M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine
- Placebo
-
Bandung, Indonesia
- +59 more
Sep 25, 2023
Chronic Kidney Disease, Type 2 Diabetes, Obesity Trial in Worldwide (Cagrilintide, Semaglutide, Placebo)
Not yet recruiting
- Chronic Kidney Disease
- +2 more
- Cagrilintide
- +2 more
-
Concord, California
- +73 more
Nov 9, 2023
Respiratory Syncytial Virus Infections Trial in Worldwide (RSVPreF3 OA Investigational Vaccine)
Not yet recruiting
- Respiratory Syncytial Virus Infections
- RSVPreF3 OA Investigational Vaccine
-
Phoenix, Arizona
- +52 more
Jun 16, 2023
Respiratory Syncytial Viruses Trial in Canada, United Kingdom, United States (RSVPreF3 OA investigational vaccine, HZ/su
Not yet recruiting
- Respiratory Syncytial Viruses
- RSVPreF3 OA investigational vaccine
- HZ/su vaccine
-
Daphne, Alabama
- +23 more
Jul 21, 2023
Chickenpox Trial in United States (Investigational varicella vaccine low potency, Investigational varicella vaccine medium
Recruiting
- Chickenpox
- Investigational varicella vaccine low potency
- +7 more
-
Bryant, Arkansas
- +49 more
Jan 24, 2023
Respiratory Syncytial Virus Infections Trial in Worldwide (RSV MAT, Placebo)
Active, not recruiting
- Respiratory Syncytial Virus Infections
- RSV MAT
- Placebo
-
Birmingham, Alabama
- +162 more
Dec 22, 2022
Tumors, Head and Neck Trial in Worldwide (Dostarlimab, Belrestotug, GSK6097608)
Not yet recruiting
- Neoplasms, Head and Neck
- Dostarlimab
- +2 more
-
New Haven, Connecticut
- +121 more
Oct 3, 2023
Diabetes, Type 2 Trial in Worldwide (Semaglutide, Empagliflozin, Metformin)
Not yet recruiting
- Diabetes Mellitus, Type 2
- Semaglutide
- +2 more
-
Toluca Lake, California
- +101 more
Oct 9, 2023
Respiratory Syncytial Virus Infections Trial in United States (RSVPreF3 OA investigational vaccine, FLU HD vaccine)
Active, not recruiting
- Respiratory Syncytial Virus Infections
- RSVPreF3 OA investigational vaccine
- FLU HD vaccine
-
Birmingham, Alabama
- +46 more
Jan 12, 2023
Type 2 Diabetes Trial in Worldwide (Cagrilintide, Semaglutide, Placebo cagrilintide)
Not yet recruiting
- Type 2 Diabetes Mellitus
- Cagrilintide
- +3 more
-
Birmingham, Alabama
- +331 more
Sep 26, 2023
Alzheimer's Disease Trial in Worldwide (GSK4527226, Placebo)
Not yet recruiting
- Alzheimer's Disease
- GSK4527226
- Placebo
-
San Diego, California
- +99 more
Oct 6, 2023
Respiratory Syncytial Virus Infections Trial (RSVPreF3 OA investigational vaccine, Placebo)
Recruiting
- Respiratory Syncytial Virus Infections
- RSVPreF3 OA investigational vaccine
- Placebo
-
Daphne, Alabama
- +56 more
Jan 20, 2023
Respiratory Syncytial Virus Infections Trial (RSVPreF3 OA investigational vaccine, FLU vaccine)
Active, not recruiting
- Respiratory Syncytial Virus Infections
- RSVPreF3 OA investigational vaccine
- FLU vaccine
-
Edegem, Belgium
- +33 more
Dec 7, 2022
Obesity, Diabetes, Type 2 Trial in Worldwide (Semaglutide, Placebo)
Recruiting
- Obesity
- Diabetes Mellitus, Type 2
- Semaglutide
- Placebo
-
Birmingham, Alabama
- +73 more
Jan 24, 2023
HIV Trial in Puerto Rico, United States (VH3810109, Cabotegravir, Standard of care (SOC))
Not yet recruiting
- HIV Infections
- VH3810109
- +3 more
-
Birmingham, Alabama
- +42 more
Aug 9, 2023
Obesity or Overweight Trial in China (Cagrilintide, Semaglutide, Placebo Semaglutide)
Not yet recruiting
- Obesity or Overweight
- Cagrilintide
- +3 more
-
Beijing, Beijing, China
- +24 more
Aug 10, 2023
Hemophilia A, Severe Trial in Worldwide (Efanesoctocog alfa)
Not yet recruiting
- Hemophilia A, Severe
- Efanesoctocog alfa
-
Vienna, Austria
- +33 more
Apr 5, 2023
Cardiovascular Risk, Acute Myocardial Infarction (AMI) Trial in India (Ziltivekimab, Placebo)
Not yet recruiting
- Cardiovascular Risk
- Acute Myocardial Infarction (AMI)
- Ziltivekimab
- Placebo
-
New Delhi, Delhi, India
- +12 more
Nov 8, 2023
Sexually Transmitted Diseases Trial in Lenexa (NgG low dose investigational vaccine, NgG medium dose investigational vaccine,
Recruiting
- Sexually Transmitted Diseases
- NgG low dose investigational vaccine
- +5 more
-
Lenexa, KansasGSK Investigational Site
Jan 6, 2023